Operating loss for the third quarter of 2019 was $6.6 million, compared to operating income of $1.1 million in the third quarter of2018.
Net loss attributable to Venus Concept Ltd. holders for the third quarter of 2019 was $8.6 million, or $1.02 per share, compared to net loss attributable to Venus Concept Ltd. holders of approximately $1.4 million, or $0.17 per share, in the third quarter of 2018. Weighted average shares used to compute net loss attributable to Venus Concept Ltd. holders per share were 8.5 million and 8.2 million for the third quarters of 2019 and 2018, respectively.
Adjusted EBITDA income for the third quarter of 2019, was $28 thousand, compared to adjusted EBITDA income of $1.7 million in the third quarter of 2018.
First Nine Months of 2019 Financial Results:
Total revenue for the nine months ended September 30, 2019 increased $4.6 million, or 6.2%, to $78.6 million, compared to $74.0 million for the nine months ended September 30, 2018. The increase in total revenue, by geography, was driven by an increase of approximately $2.2 million, or 5.4%, in international sales and an increase of $1.7 million, or 5.7%, in U.S. sales. The increase in total revenue, by product category, was driven primarily by an increase of approximately $5.2 million, or 32.3%, in system revenue, an increase of $2.6 million, or 136.2%, in service revenue and an increase of $0.9 million, or 29.0%, in product revenue which was partially offset by a decrease of $4.1 million, or 7.7%, in lease revenue compared to the prior year period.
Net loss attributable to Venus Concept Ltd. holders for the nine months ended September 30, 2019 was $19.8 million, or $2.38 per share, compared to net loss attributable to Venus Concept Ltd. holders of $1.7 million, or $0.21 per share, for the nine months ended September 30, 2018. Weighted average shares used to compute net loss attributable to Venus Concept Ltd. holders per share were 8.3 million and 8.2 million for the nine months ended September 30, 2019 and 2018, respectively.
Adjusted EBITDA loss for the nine months ended September 30, 2019 was $984 thousand, compared to adjusted EBITDA income of $7.4 million for the nine months ended September 30, 2018.
The Company had $15.7 million and $6.8 million of cash and cash equivalents as of September 30, 2019 and December 31, 2018, respectively. During the nine months ended September 30, 2019, the Company drew $10.0 million on a term loan facility with Madryn Health Partners, LP, $1.9 million on a credit facility with City National Bank of Florida and issued an aggregate principal amount of $29.1 million unsecured senior subordinated convertible promissory notes to certain existing investors. The Company had total debt obligations of approximately $98.0 million as of September 30, 2019, including line of credit borrowings of $7.6 million and convertible promissory notes of $29.4 million, compared to total debt obligations of approximately $56.5 million at December 31, 2018, including line of credit borrowings of $5.6 million.
4